Inogen (INGN) Akcija Kursas

Inogen Kursas

NASDAQ·UŽDARTAS
6,25
​
Rinka uždaryta

Per pastaruosius 14 metus Inogen pajamos augo 19,0 % kasmet ir pasiekė 348,67 mln. USD. Pelnas akcijai augo 58,1 % per metus per pastaruosius 7 metus. Inogen grynoji marža −6,5 % yra sumažėjo palyginti su −1,8 % prieš kelerius metus. Inogen 12 mėn. konsensuso tikslinė kaina yra 13,26 USD, apie virš kursą 112,2 %. Iš 8 analitikų 7 rekomenduoja pirkti — bendras konsensusas yra Pirkti.

Inogen akcijos kaina

Gaukite šiuos duomenis per Eulerpool API

100 000 užklausų/mėn. nemokamai · be kortelės

Inogen akcija ir akcijų analizė

„Inogen Inc.“ – JAV bendrovė, specializuojasi deguonies koncentratorių kūrimo ir gamybos srityje. Bendrovė įkurta 2001 m., jos būstinė įsikūrusi Goleta (Kalifornija). „Inogen“ tapo nešiojamų deguonies koncentratorių rinkos lydere JAV rinkoje. Bendrovė teikia aukštos kokybės produktus ir paslaugas, skirtus pagerinti lėtines plauts ligas sergančių pacientų gyvenimo kokybę. „Inogen“ siekia gerinti gyvenimo kokybę kurdama ir gaminant aukštos kokybės, patvarius bei patikimus nešiojamus deguonies koncentratorius, integruojančius visas būtinas funkcijas optimaliam judumui ir laisvei. Ji siūlo įvairius produktus ir paslaugas pacientams, gydytojams, draudimo kompanijoms ir bendruomenės centrams. Kai kurie iš jos produktų: „Inogen One G5“, „Inogen One G4“, „Inogen TAV“, „Inogen Carry Bag“ ir „Inogen Battery“. Apibendrinant, „Inogen Inc.“ yra specializuota bendrovė, kuri kuria ir gamina deguonies koncentratorius, su akcentu į tai, kad aukštos kokybės nešiojami sprendimai padėtų pagerinti lėtines plauts ligas sergančių pacientų gyvenimą.

Dažnai užduodami klausimai apie Inogen akciją

The business model of Inogen Inc is centered around developing and manufacturing innovative medical devices for the oxygen therapy market. Inogen primarily focuses on designing portable oxygen concentrators (POCs) that can enhance the quality of life for individuals requiring oxygen therapy. Inogen's POCs offer flexibility, mobility, and convenience, enabling patients to engage in various activities while receiving the necessary oxygen support. By providing technologically advanced and user-friendly solutions, Inogen aims to improve patient outcomes and enable individuals with respiratory conditions to lead active and independent lives. Inogen Inc is committed to meeting the evolving needs of the oxygen therapy industry by continuously developing and enhancing its product portfolio.

Inogen Inc is primarily active in the medical device industry.

The main competitors of Inogen Inc in the market are Philips Respironics and Invacare Corporation.

Inogen Inc is a renowned medical technology company specializing in the development and manufacture of portable oxygen concentrators. Founded in 2001 and based in Goleta, California, Inogen has revolutionized the industry by providing innovative and efficient oxygen therapy solutions to patients worldwide. With a strong commitment to enhancing the quality of life for those with respiratory conditions, Inogen has built a solid reputation for its cutting-edge products and exceptional customer service. The company's dedication to research, design, and manufacturing excellence has positioned it as a global leader in the oxygen therapy market, ensuring a brighter and healthier future for individuals in need of respiratory support.

Inogen Inc has achieved several significant milestones over the years. One notable achievement is the development of portable oxygen concentrators, revolutionizing the way individuals with respiratory conditions receive oxygen therapy. In 2008, the company received FDA approval for the Inogen One, its first breakthrough product. Inogen Inc has also expanded its operations globally, catering to a wider customer base across different countries. Furthermore, the company has consistently been recognized for its innovation and contributions to the medical industry. These milestones collectively highlight Inogen Inc's commitment to providing high-quality, life-enhancing solutions for individuals with respiratory needs.

Inogen Inc is primarily present in numerous countries and regions worldwide. With its focus on providing innovative and portable oxygen concentrators, Inogen has established a strong presence in various markets. The company's products and services are available across North America, including the United States and Canada, where it has a significant customer base. In addition, Inogen Inc has expanded its operations to international markets, including Europe, Australia, and Asia. Through its global distribution network and partnerships, Inogen continues to reach and serve customers in diverse geographical locations.

Inogen Inc represents values of innovation, quality, and compassion in providing portable oxygen concentrators and respiratory products. With a corporate philosophy focused on improving the quality of life for individuals with respiratory conditions, Inogen strives to enhance mobility, independence, and freedom for patients worldwide. The company's commitment to developing reliable and efficient solutions is evident through its dedication to research and development, customer service, and manufacturing excellence. Inogen Inc exemplifies its core values by providing market-leading products and exceptional support for patients to maintain an active and fulfilling lifestyle.

Analitikai šiuo metu nustato vidutinę Inogen akcijos tikslinę kainą 13,26 USD (mediana: 13,26 USD), t. y. +112,2 % palyginti su paskutine kaina. Konsensusas pagrįstas 8 analitikų reitingais.

8 analitikai šiuo metu vertina Inogen akciją: 7 rekomenduoja pirkti, 1 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Inogen gaus 356,42 mln. USD pajamų ir −0,75 USD pelno akcijai.

Pagal dabartinį kursą Inogen akcija kainuoja 5,56 EUR (6,25 USD).

Inogen akcija (INGN) kotiruojama 4 biržose, įskaitant: NASDAQ (INGN), SIX (Zürich) (6IO.SW), Frankfurt (6IO.F), Düsseldorf (6IO.DU).

Inogen Inc. is a leading health company specializing in the development, manufacturing, and distribution of respiratory therapy devices. The company's main business is the production of portable oxygen concentrators which can improve the quality of life for patients with health issues. The products offered by Inogen are innovative, space-saving, and lightweight oxygen therapy devices that allow patients to maintain their breathing during daily life activities and have more freedom and independence. These devices are usually smaller and lighter than traditional oxygen systems and designed for easy transportation and operation by patients. Inogen has three main product lines: the Inogen One G5 portable oxygen concentrator, the Inogen at Home electric oxygen concentrator, and the Inogen One G4 portable oxygen concentrator. The Inogen One G5 is a portable oxygen concentrator that offers long battery life and convenient mobility. The Inogen at Home electric oxygen concentrator is a stationary system that provides continuous oxygen supply in the private home environment. The Inogen One G4 is a portable oxygen concentrator that is even smaller and lighter than the Inogen One G5. Inogen also offers accessories for the devices including additional batteries, carrying backpacks, nasal cannulas, and other replacement parts. The company sells its products in the USA and over 30 other countries worldwide. Another business segment of Inogen is the sale of devices to third-party providers including hospitals, doctors, and other healthcare professionals. Inogen provides a comprehensive range of services including service guides, installation, and customer support. Inogen has achieved success due to its technological innovation, high product quality, and customer focus. The company engages in intensive marketing to increase brand awareness and product visibility. Inogen has successful and trained team members in sales, consultation, customer care, and technical support who meet the needs of customers. Inogen follows a co-marketing model that allows them to collaborate with other healthcare partners. These partnerships help the company present its products to a wider customer segment and develop potential business opportunities. As a socially responsible company, Inogen collaborates with various non-profit organizations to achieve its goal of improving the quality of life for patients with respiratory issues. Inogen also strives to act in an environmentally conscious manner and ensures that its devices are environmentally friendly. For example, the devices' batteries are rechargeable and the materials and components are easily reusable. Overall, Inogen's business model focuses on technological innovation, customer orientation, and social responsibility. The company utilizes its core competencies and dedicated employees to create top-notch products and provide high-quality customer service. Inogen is a sound company with robust growth potential and is well-positioned to maintain its market leadership in respiratory therapy.

tikėtina pelnas Inogen yra 356,42 mln. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.

tikėtina grynasis pelnas Inogen yra −20,32 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.

Kainų ir nuomos santykis (KGV) Inogen šiuo metu yra −8,36. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Inogen akcijos vertę.

Kainų ir pardavimų santykis (KUV) Inogen šiuo metu yra 0,48. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Inogen akcijos įvertinimo metrika.

Eulerpool kokybės balas Inogen yra 1/10.

Inogen ISIN yra US45780L1044. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.

Inogen WKN yra A1XB32. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.

Inogen prekybos žymė yra INGN. Ši biržos žymė naudojama Inogen akcijoms prekiauti biržoje.

Tikroji vertėTerminal
6,56 USD
Per/Nepakankamai vertintaTerminal
Teisingai vertinta
Sektorius
Industrija
Sveikatos priežiūros įranga ir pasiūla
Akcijų skaičius
Darbuotojai
Pajamos vienam darbuotojui
463 038,51 USD
Pajamų augimas Ø5 metai
EBIT augimas Ø5 metai
Grynojo pelno augimas Ø5 metai
Svetainė inogen.com
Valiuta
USD
Pirminis viešas pasiūlymas
2014-02-14
ISIN
US45780L1044
CUSIP
45780L104
SEDOL
BJSVLL5
Rinkos kapitalizacija
52 savaičių diapazonas
AAQS
1 / 10
PEG
—
P/E santykis
K/P santykise 2026
−8,36
K/P santykise 2027
−13,39
K/P santykise 2028
−23,63
K/P santykise 2029
125,00
K/P santykise 2030
36,76
P/S
K/A santykise
0,48
EV/EBIT
1,36
P/B santykis
0,86
ROE (nuosavo kapitalo grąža)
ROA (turto grąža)
ROCE (grąža iš panaudoto kapitalo)
ROIC (grąža iš investuoto kapitalo)
−11,83 %
Paskutinį kartą atnaujinta 2026-10-17 15:50

Inogen Biržos simbolis

DIUSELDORFAS · 6IO.DUFRANKFURTAS · 6IO.FNASDAQ · INGNSIX · 6IO.SW

Inogen FIGI

INGN:US · BBG0021PH456INGN:UA · BBG005NDSR04INGN:UC · BBG005NDSR13INGN:UN · BBG005NDSR31INGN:UP · BBG005NDSR40INGN:UB · BBG005NDSR68INGN:UM · BBG005NDSR86INGN:UX · BBG005NDSR95INGN:UD · BBG005NDSRH6INGN:UW · BBG005NDSRK2INGN:UF · BBG005NDSRL1INGN:VY · BBG005NDSRM0

Visos Inogen pagrindinės charakteristikos ir giluminė analizė

Mūsų akcijų analizė Inogen akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Inogen. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: